chartexchange

Maze Therapeutics Inc Reports Q3 2026 Net Loss of $48 Million, EPS of $0.79 Misses Estimates

GuruFocus | Nov 9, 2026 6:00 PM EST

Clinical-Stage Biotech Narrows Nine-Month Loss While Cash Position Rises to $477 Million Related Stocks: MAZE ,

Read original article